$14.500
-0.909 (-6.27%)收盤時
SMMT 資訊
SMMT 事件
Lunit and Summit Therapeutics Sign Research Agreement
Lunit and Summit Therapeutics announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained whole-slide images to characterize tumor microenvironment features. The companies aim to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies.
Summit Therapeutics Partner Akeso Announces Positive Results in Advanced Biliary Tract Cancer Study
Summit Therapeutics noted that its partner Akeso announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer. These data are featured in today's Presidential Symposium II at the European Society for Medical Oncology 2026 Congress, ESMO 2026, in Madrid, Spain. The HARMONi-GI1 presentation is entitled "Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: A randomized, controlled, double-blinded, phase 3 trial." The primary endpoint of the HARMONi-GI1 trial is overall survival and, as Akeso previously announced, a prespecified analysis showed the ivonescimab-based regimen achieved statistically significant and clinically meaningful superiority in OS compared to the durvalumab-based regimen.
Summit Therapeutics and Lunit Sign Research Agreement
Summit Therapeutics and Lunit announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained whole-slide images to characterize tumor microenvironment features. The companies aim to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies. Summit is developing ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in several solid tumors. Lunit SCOPE IO is designed to support immuno-oncology research and biomarker development through AI-powered analysis of H&E slides, enabling scalable assessment of tumor microenvironment features without requiring additional stains or assays. "Understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations," said Allen Yang, MD, PhD, Chief Research and Development Strategy Officer of Summit. "We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab."
Summit Therapeutics Collaborates with ECOG-ACRIN on Biliary Tract Cancer Trial
Summit Therapeutics announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer. The new study, EA2251, is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of patients with advanced BTC. The open-label Phase II/III EA2251 study plans to enroll patients in the U.S. who will be randomized to receive ivonescimab in combination with gemcitabine and cisplatin, or pembrolizumab or durvalumab in combination with gemcitabine and cisplatin as the established standard-of-care comparator regimen. The primary endpoint for the study is overall survival. Activation of clinical trial sites is expected to begin in the fourth quarter of 2026.
Summit Therapeutics Options Volume Normal, Implied Volatility at 4.1%
Pre-earnings options volume in Summit Therapeutics is normal with calls leading puts 19:6. Implied volatility suggests the market is anticipating a move near 4.1%, or 64c, after results are released. Median move over the past eight quarters is 11.0%.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。